Compare Boston Scientific Corporation (BSX) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Five9 Inc — how do they compare? Boston Scientific Corporation trades at $43.2 (market cap $66.37B), while Five9 Inc trades at $24.86 (market cap $1.96B). The key difference: Boston Scientific Corporation is far larger — about 33.9× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | FIVN | |
|---|---|---|
Market Cap | $66.37B | $1.96B |
Sector | Health | Technology |
52-Week High | $108.14 | $29.16 |
52-Week Low | $42.63 | $13.61 |
Enterprise Value | $75.94B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Five9 (FIVN) trades at $25.81, up 1.53% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, improving profitability, and consistent earnings beats. Recent news includes new executive appointments and AI product launches, alongside ongoing shareholder litigation concerns. Analyst consensus is bullish with a $27.00 price target.
Outlook is positive given earnings momentum and AI-driven growth, but risks include legal overhangs and competitive pressures. The stock offers upside to consensus targets if execution continues, though high valuation multiples require sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
